IEEE.

ORG IEEE XPLORE DIGITAL LIBRARY IEEE STANDARDS MORE SITES SIGN IN JOIN IEEE

NEWS BIOMEDICAL

Related Stories
Zapping the Brain and Nerves Could Treat Long
COVID Pilot studies test electrical treatments for the NEWS BIOMEDICAL

still-mysterious malady Zoom Fatigue is Real, According to

Brain Scans

BY ELIZA STRICKLAND 05 JAN 2022 7 MIN READ

FEATURE BIOMEDICAL

Can Neural Stimulation Zap

Addiction?

NEWS BIOMEDICAL

Machine Learning Turns Up COVID

Surprise

ISTOCKPHOTO

SHARE THIS STORY

New Year’s Day marked a dispiriting milestone for one New Jersey woman: 20
   months of symptoms of COVID-19. The woman, who asked for anonymity to
protect her medical privacy, suffers from a variety of neurological problems that
TAGS are associated with long COVID, including brain fog, memory problems, difficulty
BRAIN STIMULATION
reading, and extreme fatigue. In her search for treatment, she came across
NEURAL STIMULATION TDCS neurologists at New York University (NYU) who were trying electrical
VAGUS NERVE STIMULATION neurostimulation for long COVID patients. She signed up for experimental
COVID=19 treatments five days per week that send gentle electric currents through her skull
and into her cortex.

It might sound weird, she says, but the reality is quite mundane. “People ask me,
‘You’re putting electricity in your brain? Where do you go to do that?’ And I say,
‘I do it in my house, I just put on a headband and make a call.’ ”

The woman was part of a wave of people who started turning up at NYU’s
neurology clinic in the late spring of 2020, several months after the first wave of
COVID-19 cases hit New York City. “They were saying, ‘I can’t function, I can’t
return to work,’ ” remembers Leigh Charvet, a professor of neurology at NYU
Grossman School of Medicine. To make matters worse, doctors had little to offer
these patients.

Even as the world continues to grapple with new waves of acute illness, doctors
are trying to understand and find treatments for long COVID, which can trouble
patients for many months after their recovery from the initial infection. The
syndrome, technically known as post-acute sequelae of SARS-CoV-2 infection
(PASC), is associated with a long list of possible symptoms, including heart
palpitations, breathing problems, and a wide variety of neurological issues. “We
need to do so much work to understand what long COVID is,” Charvet says. “But
we also need to reach people now with something that we know is safe and
deployable.”

Researchers Step Up

Neurostimulation refers to electrical stimulation of the brain or peripheral nerves

with either implanted or external devices; it's part of a growing field that's
sometimes called bioelectronic medicine or electroceuticals. When the pandemic
hit, researchers who had been working on neurostimulation for other maladies
looked for ways to help the medical response. “This was a chance for
neuromodulation to step up,” says Marom Bikson, codirector of neural
engineering at the City College of New York and cofounder of the neurotech
company Soterix Medical, which supplied stimulation gear to several research
groups.

Some researchers began investigating whether neurostimulation could help with

the acute phase of infection. In Brazil, Suellen Andrade of the Federal University
of Paraiba recently concluded a study using transcranial direct current
stimulation (tDCS) to help patients in the intensive care unit. While her team is
still preparing a publication on the results, she says that patients who received
the stimulation (instead of a sham treatment) required significantly less time on
ventilators and were discharged sooner.

Others, including Charvet, took on long COVID. The U.S. Food and Drug
Administration (FDA) was seeking remote and scalable treatment options for
COVID-19 patients, and actively solicited proposals for neurostimulation trials
that could be carried out by patients in their own homes. While the trials so far
have been very small, the results have been promising enough to support larger
studies to optimize the technology and to test the efficacy of these treatments.

Charvet has tried tDCS with a handful of people so far. A patient puts on an
electrode-studded headband that’s attached to a controller and calls the study
coordinator, who provides a unique code to enable that day’s stimulation. During
the 20-minute stimulation session, the patient also does a therapeutic activity
such as a cognitive game, and may also do some physical exercise after the
session. Charvet says the research so far has been “a testing ground—it’s not
scientific, it’s not controlled.” Patients have come to her for help with brain fog,
fatigue, headaches, emotional dysregulation, and other problems, and she tweaks
the treatment protocols based on each person’s symptoms.

She’s now planning a larger trial with NYU patients that’s intended to optimize
the technology for at-home treatments. The trial will debut a tDCS headband
that also tracks heart-rate variability; she and her colleagues hope that this
biomarker will serve as an indicator of the patient’s response to treatment.
They’ll use a headset made by Soterix Medical that measures the impedance in
the electrodes and translates that signal into heart-rate data. “What drives us is
that there’s a tremendous unmet need,” Charvet says. “And our patients are
getting better.”

At the Medical University of South Carolina, psychiatry professor Mark George

tried a different neurostimulation approach in a pilot study of 20 patients that he
began in late 2020; his study used an at-home device that stimulated the vagus
nerve through the ear. George’s team assembled a “real tough briefcase with a
whole bunch of good stuff inside,’ ” he says, likening the equipment to Mission
Impossible supplies. Each patient got an iPad for telemedicine consultations and
for symptom surveys, the stimulation device, and “a portable ICU” with
wearables that measured heart rate, oxygen saturation, and blood pressure.
George’s patients did 1-hour sessions each morning and evening, six days per
week, while seated and doing whatever they wished.

“We showed you could do this kind of stimulation at home; the safety data was
impeccable,” George says. “And we saw reductions in brain fog, improvements in
energy, some improvement in anxiety.” He’s now applying for funding for a larger
study.

One of his patients, a woman in her 60s who asked to be identified only by her
first name, Pam, says she suffered from brain fog, memory lapses, fatigue, and
mood swings following her case of COVID-19, which sent her to the emergency
room in April 2020. When she started the stimulation, she felt a lessening of the
uncharacteristic depression and anger that had troubled her, she says. “When I
started with the treatment, I felt a little brighter, more like myself,” Pam says. “I
think I was a little better mentally.” Another participant, a woman in her 50s who
asked to be identified only as Beth, spent 23 days in the hospital during her initial
battle with COVID-19, including more than a week in the intensive care unit. A
few weeks after she started the stimulation, “I noticed improvements in my
headaches,” Beth says, “and also with the vertigo.” Both women say their
symptoms returned when the study ended, although not with the same intensity.

Disentangling Everything

One of the challenges that researchers face as they investigate the utility of
neurostimulation for long COVID is the diversity of symptoms that patients
report. George says his study deliberately took a “shotgun approach,” enrolling
patients with a variety of neurological symptoms and looking at who responded
best to the treatment. More work is needed to clarify which stimulation methods
are most effective for which subsets of patients.

What’s more, there are a host of confounding factors at play, notes Jennifer
Frontera, a professor of neurology at NYU Grossman School of Medicine. “It’s a
very heterogenous group of people describing very heterogenous symptoms,” she
says. NYU initially become a hub for research on long COVID because the
hospital saw so many patients in the first wave of the pandemic and has tracked
released patients over time. In September 2021, the National Institutes of Health
put the institution in charge of a US $470 million grant to support large-scale
studies of Long COVID. Frontera notes that a big part of that project, called the
Researching COVID to Enhance Recovery (RECOVER) Initiative, will be
disentangling everything.

“We don’t have a medication for brain fog.”

—Jennifer Frontera, NYU

Frontera explains that some people dealing with long COVID may have
experienced low levels of oxygen in their brains during their acute illness, while
others may have immune systems that went into overdrive following COVID-19
infection. But others may be experiencing a worsening of underlying conditions
such as mood disorders and dementia, and still others may be having symptoms
that aren’t actually related to their COVID-19 infections. “Many people are sitting
around their houses, they’re not out walking around,” she says. “Some people are
more in tune with their bodies and are noticing things they never noticed before.”
Even the weight gain that’s been so common during the pandemic can confuse
matters since it can lead to sleep apnea, which in turn can cause sleep problems,
fatigue, and headaches.

To get a handle on the basics, Frontera and her colleagues conducted a study
about health impacts of the pandemic, surveying 1,000 people whose
demographics roughly matched those of the United States in terms of age,
gender, and ethnicity. They didn’t ask participants if they’d been infected with
COVID-19 until the end. They found that pandemic-related stress factors such as
financial and relationship problems were equally predictive of anxiety,
depression, and insomnia as a history of COVID-19 infection. However, a history
of infection was more predictive of cognitive issues.

Frontera doesn’t see the study’s result as undercutting the severity of the long
COVID problem. She notes that the study found that 25 percent of people with a
history of COVID-19 had symptoms that persisted beyond a month. “If you
translate that out to the population of the United States, that would be 6 million
people,” she says. She’s most troubled by the cognitive problems she’s seeing, she
says: “Wedon’t have a medication for brain fog.”

Frontera and her colleagues have also been following people who have been
hospitalized because of COVID-19; they published a paper regarding the
patient’s status six months after infection and recently submitted a paper with
data from one year after infection. Even after one year, she says, 80 percent of
those people were still experiencing symptoms, and 50 percent scored as
abnormal on a cognitive screening tool. “That’s a lot of cognitive disability,” she
says.

Searching for the “Why”

If neurostimulation does help with the neurological symptoms of long COVID,

it’s not clear why. Stimulation with tDCS has been shown to increase “plasticity”
in the brain, or the ability of the brain to make new connections between
neurons; neuroplasticity is associated with learning, changing thought patterns,
and rehabilitation after injury. Vagus-nerve stimulation has been shown to
reduce inflammation in the body, which is a component of autoimmune
disorders; if some long haulers are suffering from an overactive immune system,
vagus-nerve stimulation could help. George in South Carolina hopes to collect
biomarkers associated with inflammation in his next study to examine that
possible connection.

The researchers are hoping that larger studies will begin to shed light on the
ways that neurostimulation impacts the neurology of people with long COVID.
And if millions of people in the United States alone are in need of treatment, they
may have an unprecedented opportunity for research.

Marom Bikson of Soterix Medical notes that both the research field and the
industry of neurostimulation is just getting started. “We don’t have Pfizers of
neuromodulation,” he says, “but you can only imagine what would happen if it
shows an effect on long COVID.” It could lead to millions of people having
stimulators in their homes, he suggests, which could open other doors. “Once
you start stimulating for long COVID, you can start stimulating for other things
like depression,” he says. But he says it’s crucial to proceed cautiously and not
make unsupported claims for neurostimulation’s powers. “Otherwise,” he says,
“it could have the opposite effect.”

MORE FROM SPECTRUM

Researcher O@ers an Answer to Scientific Controversy Over Brain ... ›

Handheld Vagus Nerve Stimulator Gets Emergency Approval for ... ›

The Vagus Nerve: A Back Door for Brain Hacking - IEEE Spectrum ›

The Algorithm that Mapped Omicron Shows a Path Forward - IEEE Spectrum
›

Nerve Coolers: Pain Relief Without Drugs - IEEE Spectrum ›

AROUND THE WEB

What Is Neurostimulation? Neurostimulators for Chronic Pain from ... ›

Vagus nerve stimulation - Mayo Clinic ›

tDCS Program | NYU Langone Health ›

ABOUT THE AUTHOR

Eliza Strickland is a senior editor at IEEE Spectrum, where she covers AI, biomedical engineering, and other
topics. See full bio →

READER RESPONSES SORT BY POPULAR

Add comment...

PUBLISH

6 JAN 2022
ZIHAO ZENG
good

REPLY SHARE

READ ALSO

NEWS AEROSPACE

Boosting Laser Power Will Help Them Blast Drones

4 HOURS AGO 4 MIN READ

NEWS BIOMEDICAL

Neuralink Barrels Into Human Tests Despite Fraud

Claims
6 HOURS AGO 4 MIN READ

NEWS THE INSTITUTE

Artificial
This website utilizes technologies such as cookies to enable essential site Intelligence
functionality, isanalytics,
as well as for a Top Priority for Tech
personalization, and Leaders
targeted advertising
in 2024
purposes. You may change your settings at any time or accept the default settings. You may close this banner to continue with only essential cookies.
SAVE
Privacy Policy 05 DEC 2023 3 MIN READ
ACCEPT ALL
Storage Preferences
REJECT ALL
Targeted Advertising
Personalization Analytics